Evidence comparison

Retatrutide vs Cagrilintide

Retatrutide and cagrilintide target different pathways and both remain investigational as standalone obesity programs. There is no head-to-head trial.

Compare mechanisms

Receptor targets differ, which changes the scientific hypothesis.

Compare approval status

Approved labeling and investigational trial data are different evidence levels.

Avoid cross-trial ranking

Populations, durations, estimands, and protocols differ across studies.

Side-by-side evidence map

Question	Retatrutide	Cagrilintide
Mechanism	GLP-1, GIP, and glucagon agonism	Long-acting amylin analog
Development context	Studied as a single triple agonist	Often studied with semaglutide as CagriSema
Regulatory status	Investigational	Investigational
Direct comparison	No head-to-head trial	No head-to-head trial

How to read the numbers

A larger percentage reported in one trial does not prove superiority over a result from another trial. A valid treatment comparison requires a head-to-head design or a carefully specified indirect analysis.